Nippon India BSE Sensex Next 30 Index Fund
The scheme seeks to provide investment returns that commensurate to the total returns of the securities as represented by the BSE Sensex Next 30 Index before expenses, subject to tracking errors.
Growthvine rating: 3/5 — ranked #20 of 42 in category.
Fund basics
| Category | Equity: Large Cap |
|---|
| NAV | ₹9.93 (as of 2026-10-23) |
|---|
| AUM | ₹87 Cr |
|---|
| Expense ratio | 0.44% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Himanshu Mange |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −12.13% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 108.6% of NIFTY 100's upside and 67.4% of its downside.
Market cap allocation
| Large cap | 87.0% |
|---|
| Mid cap | 12.9% |
|---|
| Small cap | 0.0% |
|---|
Concentration
| Top 5 holdings | 25.1% |
|---|
| Top 10 holdings | 45.4% |
|---|
| Total holdings | 30 |
|---|
| Index overlap | 18.1% |
|---|
| Active share | 81.9% |
|---|
Top holdings
- Shriram Finance Limited — 5.5%
- Hindalco Industries Ltd. — 5.4%
- JSW Steel Limited — 4.8%
- Divis Laboratories Ltd. — 4.7%
- Bajaj Auto Limited — 4.6%
- Grasim Industries Ltd — 4.6%
- Coal India Limited — 4.1%
- Eicher Motors Ltd. — 3.9%
- Adani Enterprises Ltd. — 3.9%
- TVS Motor Company Ltd. — 3.8%
Top sectors
- Automobile — 17.5%
- Finance & Investments — 11.1%
- Pharma & Biotech — 10.8%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −5.7% | Q1 (Top) | #4 of 39 |